177 related articles for article (PubMed ID: 29156899)
1. Modulating the endocannabinoid pathway as treatment for peripheral neuropathic pain: a selected review of preclinical studies.
O'Hearn S; Diaz P; Wan BA; DeAngelis C; Lao N; Malek L; Chow E; Blake A
Ann Palliat Med; 2017 Dec; 6(Suppl 2):S209-S214. PubMed ID: 29156899
[TBL] [Abstract][Full Text] [Related]
2. The maintenance of cisplatin- and paclitaxel-induced mechanical and cold allodynia is suppressed by cannabinoid CB₂ receptor activation and independent of CXCR4 signaling in models of chemotherapy-induced peripheral neuropathy.
Deng L; Guindon J; Vemuri VK; Thakur GA; White FA; Makriyannis A; Hohmann AG
Mol Pain; 2012 Sep; 8():71. PubMed ID: 22998838
[TBL] [Abstract][Full Text] [Related]
3. Chronic cannabinoid receptor 2 activation reverses paclitaxel neuropathy without tolerance or cannabinoid receptor 1-dependent withdrawal.
Deng L; Guindon J; Cornett BL; Makriyannis A; Mackie K; Hohmann AG
Biol Psychiatry; 2015 Mar; 77(5):475-87. PubMed ID: 24853387
[TBL] [Abstract][Full Text] [Related]
4. Prophylactic cannabinoid administration blocks the development of paclitaxel-induced neuropathic nociception during analgesic treatment and following cessation of drug delivery.
Rahn EJ; Deng L; Thakur GA; Vemuri K; Zvonok AM; Lai YY; Makriyannis A; Hohmann AG
Mol Pain; 2014 Apr; 10():27. PubMed ID: 24742127
[TBL] [Abstract][Full Text] [Related]
5. Endocannabinoids decrease neuropathic pain-related behavior in mice through the activation of one or both peripheral CB₁ and CB₂ receptors.
Desroches J; Charron S; Bouchard JF; Beaulieu P
Neuropharmacology; 2014 Feb; 77():441-52. PubMed ID: 24148808
[TBL] [Abstract][Full Text] [Related]
6. Changes in the expression of endocannabinoid system components in an experimental model of chemotherapy-induced peripheral neuropathic pain: Evaluation of sex-related differences.
Noya-Riobó MV; Miguel CÁ; Soriano DB; Brumovsky PR; Villar MJ; Coronel MF
Exp Neurol; 2023 Jan; 359():114232. PubMed ID: 36179876
[TBL] [Abstract][Full Text] [Related]
7. Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats.
Rahn EJ; Zvonok AM; Thakur GA; Khanolkar AD; Makriyannis A; Hohmann AG
J Pharmacol Exp Ther; 2008 Nov; 327(2):584-91. PubMed ID: 18664590
[TBL] [Abstract][Full Text] [Related]
8. CB1 Knockout Mice Unveil Sustained CB2-Mediated Antiallodynic Effects of the Mixed CB1/CB2 Agonist CP55,940 in a Mouse Model of Paclitaxel-Induced Neuropathic Pain.
Deng L; Cornett BL; Mackie K; Hohmann AG
Mol Pharmacol; 2015 Jul; 88(1):64-74. PubMed ID: 25904556
[TBL] [Abstract][Full Text] [Related]
9. Targeting the Endocannabinoid System for Prevention or Treatment of Chemotherapy-Induced Neuropathic Pain: Studies in Animal Models.
Masocha W
Pain Res Manag; 2018; 2018():5234943. PubMed ID: 30147813
[TBL] [Abstract][Full Text] [Related]
10. Spinal anandamide produces analgesia in neuropathic rats: possible CB(1)- and TRPV1-mediated mechanisms.
Starowicz K; Makuch W; Osikowicz M; Piscitelli F; Petrosino S; Di Marzo V; Przewlocka B
Neuropharmacology; 2012 Mar; 62(4):1746-55. PubMed ID: 22178705
[TBL] [Abstract][Full Text] [Related]
11. Endocannabinoid regulation of spinal nociceptive processing in a model of neuropathic pain.
Sagar DR; Jhaveri MD; Richardson D; Gray RA; de Lago E; Fernández-Ruiz J; Barrett DA; Kendall DA; Chapman V
Eur J Neurosci; 2010 Apr; 31(8):1414-22. PubMed ID: 20384778
[TBL] [Abstract][Full Text] [Related]
12. The multiplicity of spinal AA-5-HT anti-nociceptive action in a rat model of neuropathic pain.
Malek N; Kostrzewa M; Makuch W; Pajak A; Kucharczyk M; Piscitelli F; Przewlocka B; Di Marzo V; Starowicz K
Pharmacol Res; 2016 Sep; 111():251-263. PubMed ID: 27326920
[TBL] [Abstract][Full Text] [Related]
13. Endocannabinoids and Their Pharmacological Actions.
Pertwee RG
Handb Exp Pharmacol; 2015; 231():1-37. PubMed ID: 26408156
[TBL] [Abstract][Full Text] [Related]
14. Combined inhibition of monoacylglycerol lipase and cyclooxygenases synergistically reduces neuropathic pain in mice.
Crowe MS; Leishman E; Banks ML; Gujjar R; Mahadevan A; Bradshaw HB; Kinsey SG
Br J Pharmacol; 2015 Apr; 172(7):1700-12. PubMed ID: 25393148
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic treatment with the tricyclic antidepressant desipramine prevents development of paclitaxel-induced neuropathic pain through activation of endogenous analgesic systems.
Deng L; Lee WH; Xu Z; Makriyannis A; Hohmann AG
Pharmacol Res; 2016 Dec; 114():75-89. PubMed ID: 27773824
[TBL] [Abstract][Full Text] [Related]
16. Endocannabinoid System as a Promising Therapeutic Target in Inflammatory Bowel Disease - A Systematic Review.
Hryhorowicz S; Kaczmarek-Ryś M; Zielińska A; Scott RJ; Słomski R; Pławski A
Front Immunol; 2021; 12():790803. PubMed ID: 35003109
[TBL] [Abstract][Full Text] [Related]
17. Effects of Se-phenyl thiazolidine-4-carboselenoate on mechanical and thermal hyperalgesia in brachial plexus avulsion in mice: mediation by cannabinoid CB1 and CB2 receptors.
Del Fabbro L; Borges Filho C; Cattelan Souza L; Savegnago L; Alves D; Henrique Schneider P; de Salles HD; Jesse CR
Brain Res; 2012 Sep; 1475():31-6. PubMed ID: 22902772
[TBL] [Abstract][Full Text] [Related]
18. Gender differences in a mouse model of chemotherapy-induced neuropathic pain.
Naji-Esfahani H; Vaseghi G; Safaeian L; Pilehvarian AA; Abed A; Rafieian-Kopaei M
Lab Anim; 2016 Feb; 50(1):15-20. PubMed ID: 25732574
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of anandamide hydrolysis attenuates nociceptor sensitization in a murine model of chemotherapy-induced peripheral neuropathy.
Uhelski ML; Khasabova IA; Simone DA
J Neurophysiol; 2015 Mar; 113(5):1501-10. PubMed ID: 25505113
[TBL] [Abstract][Full Text] [Related]
20. Modulating the endocannabinoid system in human health and disease--successes and failures.
Pacher P; Kunos G
FEBS J; 2013 May; 280(9):1918-43. PubMed ID: 23551849
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
